Observations placeholder

Sci Rep. 2018 Jan 29;8(1):1732. doi: 10.1038/s41598-017-18618-x.
Antimicrobial activity of apple cider vinegar against Escherichia coli, Staphylococcus aureus and Candida albicans; downregulating cytokine and microbial protein expression.
Yagnik D1, Serafin V2, J Shah A2.
Author information
1
Department of Natural Sciences, School of Science and Technology, Middlesex University, The Burroughs, London, NW4 4BT, England, United Kingdom. d.yagnik@mdx.ac.uk.
2
Department of Natural Sciences, School of Science and Technology, Middlesex University, The Burroughs, London, NW4 4BT, England, United Kingdom.

Abstract
The global escalation in antibiotic resistance cases means alternative antimicrobials are essential. The aim of this study was to investigate the antimicrobial capacity of apple cider vinegar (ACV) against

• E. coli,
• S. aureus and
• C. albicans.

The minimum dilution of ACV required for growth inhibition varied for each microbial species.

• For C. albicans, a 1/2 ACV had the strongest effect,
• S. aureus, a 1/25 dilution ACV was required, whereas for
• E-coli cultures, a 1/50 ACV dilution was required (p < 0.05).

Monocyte co-culture with microbes alongside ACV resulted in dose dependent downregulation of inflammatory cytokines (TNFα, IL-6). Results are expressed as percentage decreases in cytokine secretion comparing ACV treated with non-ACV treated monocytes cultured with E-coli (TNFα, 99.2%; IL-6, 98%), S. aureus (TNFα, 90%; IL-6, 83%) and C. albicans (TNFα, 83.3%; IL-6, 90.1%) respectively.

Proteomic analyses of microbes demonstrated that ACV impaired cell integrity, organelles and protein expression. ACV treatment resulted in an absence in expression of DNA starvation protein, citrate synthase, isocitrate and malate dehydrogenases in E-coli; chaperone protein DNak and ftsz in S. aureus and pyruvate kinase, 6-phosphogluconate dehydrogenase, fructose bisphosphate were among the enzymes absent in C.albican cultures.

The results demonstrate ACV has multiple antimicrobial potential with clinical therapeutic implications.
PMID:
29379012
PMCID:
PMC5788933
DOI:
10.1038/s41598-017-18618-x